[ExI] way to go brits!

Dylan Distasio interzone at gmail.com
Sat Dec 31 03:37:40 UTC 2022


Rafal-

Thanks for the thoughtful reply.   I will admit on reflection that I may be
guilty of throwing the baby out with the bathwater.   I definitely see the
potential of mRNA tech, and the melanoma trial you mentioned is very
exciting to hear about (I wasn't aware of it).

My two big concerns with the tech are that the nanoparticles get wide
distribution in multiple organ systems, and that the modification to keep
the mRNA stable is problematic.    Out of curiosity, do you know if the
melanoma vaccine is using N1-methyl-pseudouridine like the WuFlu ones are?
 I'm curious if the same shift in immunoglobulins to IgG4 is seen with the
melanoma vaccine, but would suspect it won't be if N1-methyl-pseudouridine
is not used in the formulation.

I'll have to read up on it though!

As far as the current crimes against humanity, I suspect a lot of the
problems are coming from the manufactured spike protein interacting with
endothelial cells lining the blood vessels, but that is just speculation
until some actual science is allowed to be done on it.


On Fri, Dec 30, 2022 at 9:48 PM Rafal Smigrodzki via extropy-chat <
extropy-chat at lists.extropy.org> wrote:

>
>
> However, this does not necessarily mean that mRNA vaccines are bad for
> you. If you use mRNA to generate a non-toxic but highly antigenic target
> you should be able to stimulate an immune response without causing unusual
> toxicity. There are a bunch of mRNA vaccines in the works and so far I
> haven't heard about a general problem with them. The new personalized
> melanoma vaccine greatly reduces risk of recurrence or death - by 44%. The
> vaccine is a marvel - it combines dozens of individually created
> neo-antigens specifically tailored to a patient's tumor - and created
> within about a week for each patient!
>
>
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.extropy.org/pipermail/extropy-chat/attachments/20221230/258ce814/attachment.htm>


More information about the extropy-chat mailing list